Description
Refortan 130 (hydroxyethyl starch, sodium chloride) Solution for Infusions 500 ml. №1 Vial
Ingredients
- Refortan 130 contains hydroxyethyl starch and sodium chloride as active ingredients.
Dosage
- The dosage of Refortan 130 should be determined by a healthcare professional based on individual patient needs. It is administered intravenously.
Indications
- Refortan 130 is indicated for the treatment of hypovolemia (low blood volume) and shock. It helps to restore blood volume and improve circulation.
Contraindications
- Do not use Refortan 130 in patients with known hypersensitivity to hydroxyethyl starch or sodium chloride. It is also contraindicated in patients with severe renal impairment.
Directions
- Administer Refortan 130 intravenously as directed by a healthcare provider. Monitor the patient for any signs of fluid overload or adverse reactions during infusion.
Scientific Evidence
- Refortan 130, a colloid solution containing hydroxyethyl starch, has been studied extensively for its efficacy in treating hypovolemia and shock. Research suggests that hydroxyethyl starch solutions can effectively increase intravascular volume and improve hemodynamic stability in critically ill patients.
Additional Information
- In clinical trials, Refortan 130 has shown to be a valuable option in the management of hypovolemia due to its ability to rapidly expand plasma volume. It is important to carefully monitor patients receiving hydroxyethyl starch solutions for potential adverse effects such as coagulopathy and renal impairment.
Pharmacological Effects
- Hydroxyethyl starch in Refortan 130 works by increasing plasma volume, which helps to improve tissue perfusion and oxygen delivery. This can be beneficial in conditions where there is a loss of intravascular volume, such as in shock.
Comparative Effectiveness
- Compared to crystalloid solutions, colloid solutions like Refortan 130 have been shown to provide more sustained volume expansion and hemodynamic stability in critically ill patients. However, the choice between colloid and crystalloid solutions should be based on individual patient factors and clinical judgment.
